Autopsy report · NCT00929669

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

“unable to identify a third subject”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 6 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Pennsylvania

Sponsor type

University, hospital or other

Conditions

Gonadotroph Adenomas

Interventions

pasireotide LAR

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis
  “Not able to find enough subjects” (65% match in meaning)
• Impact of Sleep Apnea on Diabetic Foot Wound.
  “Difficulty including subjects corresponding to the criteria.” (60% match in meaning)
• Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
  “Difficulty in identifying subjects satisfying the inclusion criteria.” (57% match in meaning)
• Osteopathic Intervention in Professional Handball Players
  “no more possibly to include subjects (subject unavailability)” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.